Henry Schein (NASDAQ:HSIC) Sets New 52-Week High on Better-Than-Expected Earnings

Henry Schein, Inc. (NASDAQ:HSIC)’s share price reached a new 52-week high during trading on Tuesday following a stronger than expected earnings report. The company traded as high as $89.29 and last traded at $87.6710, with a volume of 744143 shares trading hands. The stock had previously closed at $80.57.

The company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. During the same period in the previous year, the firm earned $1.19 EPS. The company’s revenue was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS.

Key Stories Impacting Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q4 EPS and revenue beat — Henry Schein reported $1.34 EPS vs. $1.30 consensus and revenue up ~7.7% year‑over‑year, driven by strength in dental and medical equipment. This beat supports near‑term earnings momentum. Reuters: Henry Schein beats quarterly profit estimates
• Positive Sentiment: Revenue guidance raised above consensus — Management gave revenue guidance of roughly $13.6–$13.8 billion, modestly above consensus, signaling confidence in demand recovery for equipment and specialty offerings. Press Release / Slide Deck
• Positive Sentiment: Analyst upgrade — Robert W. Baird upgraded HSIC to “outperform” and raised its price target to $100, which likely attracted buyers and validated the recovery story. MSN: Baird upgrades Henry Schein
• Neutral Sentiment: FY‑2026 EPS guidance largely in line — Management provided an EPS range of 5.230–5.370 vs. consensus ~5.28, so guidance neither materially disappoints nor exceeds expectations; the company reiterated its outlook alongside the results. Press Release / Slide Deck
• Neutral Sentiment: Investor materials and call available — Management released a press deck and held a conference call (useful for detail on equipment demand and margin outlook). MarketBeat: Listen to Conference Call
• Negative Sentiment: Margin contraction — Gross and operating margins declined, tempering the beat and suggesting cost or product‑mix pressures even as equipment and specialty sales recover; margin trends will be watched closely in coming quarters. Zacks: HSIC Q4 earnings & revenues beat; margins down

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Evercore upped their price objective on Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Robert W. Baird set a $100.00 target price on Henry Schein and gave the stock an “outperform” rating in a report on Monday. JPMorgan Chase & Co. increased their price objective on shares of Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, Barrington Research set a $79.00 price objective on shares of Henry Schein and gave the company an “outperform” rating in a report on Wednesday, November 5th. Six investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $78.75.

Institutional Investors Weigh In On Henry Schein

A number of institutional investors and hedge funds have recently made changes to their positions in HSIC. CYBER HORNET ETFs LLC purchased a new stake in shares of Henry Schein during the second quarter valued at approximately $25,000. MUFG Securities EMEA plc bought a new stake in Henry Schein in the 2nd quarter worth $27,000. Flagship Harbor Advisors LLC bought a new stake in Henry Schein in the 4th quarter worth $30,000. Federated Hermes Inc. purchased a new position in shares of Henry Schein in the fourth quarter valued at about $32,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Henry Schein during the fourth quarter valued at about $37,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Price Performance

The business has a 50 day moving average of $77.43 and a 200 day moving average of $71.78. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.40 and a quick ratio of 0.79. The company has a market cap of $10.19 billion, a PE ratio of 27.46, a price-to-earnings-growth ratio of 2.37 and a beta of 0.88.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.